Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer

Laura Evangelista; Zora Baretta; Lorenzo Vinante; Anna Rita Cervino; Michele Gregianin; Cristina Ghiotto; Giorgio Saladini; Guido Sotti

doi:10.1007/s00259-010-1626-7

Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer

Laura Evangelista, Zora Baretta, Lorenzo Vinante, Anna Rita Cervino, Michele Gregianin, Cristina Ghiotto, Giorgio Saladini, Guido Sotti

Istituto Oncologico Veneto

Research output: Contribution to journal › Article › peer-review

Abstract

Purpose: The aim of the study was to assess the role of CA 15.3, CT and positron emission tomography (PET)/CT in patients with breast cancer and suspected disease relapse after primary treatment. Methods: We studied 111 consecutive patients (mean age 61±12 years) with previous breast cancer, already treated and with clinical or biochemical suspicion of disease relapse. All patients underwent CT and ¹⁸F-fluorodeoxyglucose (FDG) PET/CT. In all patients, the value of CA 15.3 was compared to PET/CT and CT. The final diagnosis of relapse was established by invasive and noninvasive follow-up and was compared with CA 15.3, CT and PET/CT results. Univariate and multivariate analyses were used to identify the independent predictors of disease relapse and receiver-operating characteristic (ROC) curve for the identification of optimal CA 15.3 cutoff. Results: Of all patients, 40 (36%) showed an increased CA 15.3 value, CT was positive in 73 (66%), whereas at PET/CT imaging 64 (58%) showed positive findings for disease relapse. Of 40 patients with increased marker levels, 22 patients had positive CT and 30 positive PET/CT (55 vs 75%, p

Original language	English
Pages (from-to)	293-301
Number of pages	9
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	38
Issue number	2
DOIs	https://doi.org/10.1007/s00259-010-1626-7
Publication status	Published - Feb 2011

Keywords

Breast cancer
Disease relapse
Follow-up
Positron emission tomography
Tumour markers

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s00259-010-1626-7

Fingerprint Dive into the research topics of 'Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer'. Together they form a unique fingerprint.

Cite this

Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer. / Evangelista, Laura; Baretta, Zora; Vinante, Lorenzo; Cervino, Anna Rita; Gregianin, Michele; Ghiotto, Cristina; Saladini, Giorgio; Sotti, Guido.

In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, No. 2, 02.2011, p. 293-301.

Research output: Contribution to journal › Article › peer-review

@article{736b5b05144e45c1bf3f95205f5c4993,

title = "Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer",

abstract = "Purpose: The aim of the study was to assess the role of CA 15.3, CT and positron emission tomography (PET)/CT in patients with breast cancer and suspected disease relapse after primary treatment. Methods: We studied 111 consecutive patients (mean age 61±12 years) with previous breast cancer, already treated and with clinical or biochemical suspicion of disease relapse. All patients underwent CT and 18F-fluorodeoxyglucose (FDG) PET/CT. In all patients, the value of CA 15.3 was compared to PET/CT and CT. The final diagnosis of relapse was established by invasive and noninvasive follow-up and was compared with CA 15.3, CT and PET/CT results. Univariate and multivariate analyses were used to identify the independent predictors of disease relapse and receiver-operating characteristic (ROC) curve for the identification of optimal CA 15.3 cutoff. Results: Of all patients, 40 (36%) showed an increased CA 15.3 value, CT was positive in 73 (66%), whereas at PET/CT imaging 64 (58%) showed positive findings for disease relapse. Of 40 patients with increased marker levels, 22 patients had positive CT and 30 positive PET/CT (55 vs 75%, p",

keywords = "Breast cancer, Disease relapse, Follow-up, Positron emission tomography, Tumour markers",

author = "Laura Evangelista and Zora Baretta and Lorenzo Vinante and Cervino, {Anna Rita} and Michele Gregianin and Cristina Ghiotto and Giorgio Saladini and Guido Sotti",

year = "2011",

month = feb,

doi = "10.1007/s00259-010-1626-7",

language = "English",

volume = "38",

pages = "293--301",

journal = "European Journal of Pediatrics",

issn = "0340-6199",

publisher = "Springer Berlin Heidelberg",

number = "2",

}

TY - JOUR

T1 - Tumour markers and FDG PET/CT for prediction of disease relapse in patients with breast cancer

AU - Evangelista, Laura

AU - Baretta, Zora

AU - Vinante, Lorenzo

AU - Cervino, Anna Rita

AU - Gregianin, Michele

AU - Ghiotto, Cristina

AU - Saladini, Giorgio

AU - Sotti, Guido

PY - 2011/2

Y1 - 2011/2

N2 - Purpose: The aim of the study was to assess the role of CA 15.3, CT and positron emission tomography (PET)/CT in patients with breast cancer and suspected disease relapse after primary treatment. Methods: We studied 111 consecutive patients (mean age 61±12 years) with previous breast cancer, already treated and with clinical or biochemical suspicion of disease relapse. All patients underwent CT and 18F-fluorodeoxyglucose (FDG) PET/CT. In all patients, the value of CA 15.3 was compared to PET/CT and CT. The final diagnosis of relapse was established by invasive and noninvasive follow-up and was compared with CA 15.3, CT and PET/CT results. Univariate and multivariate analyses were used to identify the independent predictors of disease relapse and receiver-operating characteristic (ROC) curve for the identification of optimal CA 15.3 cutoff. Results: Of all patients, 40 (36%) showed an increased CA 15.3 value, CT was positive in 73 (66%), whereas at PET/CT imaging 64 (58%) showed positive findings for disease relapse. Of 40 patients with increased marker levels, 22 patients had positive CT and 30 positive PET/CT (55 vs 75%, p

AB - Purpose: The aim of the study was to assess the role of CA 15.3, CT and positron emission tomography (PET)/CT in patients with breast cancer and suspected disease relapse after primary treatment. Methods: We studied 111 consecutive patients (mean age 61±12 years) with previous breast cancer, already treated and with clinical or biochemical suspicion of disease relapse. All patients underwent CT and 18F-fluorodeoxyglucose (FDG) PET/CT. In all patients, the value of CA 15.3 was compared to PET/CT and CT. The final diagnosis of relapse was established by invasive and noninvasive follow-up and was compared with CA 15.3, CT and PET/CT results. Univariate and multivariate analyses were used to identify the independent predictors of disease relapse and receiver-operating characteristic (ROC) curve for the identification of optimal CA 15.3 cutoff. Results: Of all patients, 40 (36%) showed an increased CA 15.3 value, CT was positive in 73 (66%), whereas at PET/CT imaging 64 (58%) showed positive findings for disease relapse. Of 40 patients with increased marker levels, 22 patients had positive CT and 30 positive PET/CT (55 vs 75%, p

KW - Breast cancer

KW - Disease relapse

KW - Follow-up

KW - Positron emission tomography

KW - Tumour markers

UR - http://www.scopus.com/inward/record.url?scp=79551559469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551559469&partnerID=8YFLogxK

U2 - 10.1007/s00259-010-1626-7

DO - 10.1007/s00259-010-1626-7

M3 - Article

C2 - 20882280

AN - SCOPUS:79551559469

VL - 38

SP - 293

EP - 301

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 2

ER -